Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company CytImmune Sciences Inc.
Description mAb against interleukin-2 (IL-2)
Molecular Target Interleukin-2 (IL-2)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentDiscovery
Standard IndicationLeukemia
Indication DetailsTreat adult T cell leukemia
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today